检索结果-南通市图书馆

A multicenter prospective study on the management of hepatoblastoma in children:a report from the Chinese Children's Cancer Group

引用

World Journal of Pediatrics 2024年第6期20卷 590-601页

作者： Meng-Jie Tang Xiao-Li Ma Xiang-Ling He Wei-Hua Pan Xiao-Hong Zhang Sha-Yi Jiang Ju Gao Fu Li Wei Yao Song Gu Wei-Ling Zhang Qiang Zhao Shi-Hao Huang Yong-Jun Fang Wei Liu Hui-Zhong Niu Chun-Mei Wang Li-Rong Sun Hui Gao Yun-Peng Dai Shun-Gen Huang Zhi-Yong Zhong Xi-Ge Wang Zhong-Rong Li Liang-Chun Yang Ye-Ming Wu Huan-Min Wang Xin Sun Xiao-Jun Yuan department of Pediatric Hematology/oncology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineNo.1665Kongjiang RoadYangpu DistrictShanghai 200092China Medical oncology department Pediatric Oncology CenterBeijing Children's HospitalCapital Medical UniversityNational Center for Children's HealthBeijing 100045China department of Hematology/oncology Children's Medical CenterHunan Provincial People's HospitalThe First Affiliated Hospital of Hunan Normal UniversityChangsha 41005China department of Pediatric Surgery Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200092China department of Hematology/oncology Guangzhou Women and Children's Medical CenterNational Children's Medical Center for South Central RegionGuangzhou 510623China department of Hematology Shanghai Children's HospitalShanghai Jiao Tong UniversityShanghai 200062China department of Pediatrics West China Second University HospitalSichuan UniversityChengdu 610041China department of Hematology/oncology Qilu Children's Hospital of Shandong UniversityJinan 250022China department of Pediatric Surgery Children's Hospital of Fudan UniversityShanghai 201102China department of General Surgery Shanghai Children's Medical Center(National Children's Medical Center-Shanghai)Shanghai Jiao Tong University School of MedicineShanghai 200127China department of Pediatrics Beijing Tongren HospitalCapital Medical UniversityBeijing 100730China department of Pediatric oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060China department of Hematology/oncology Children's Hospital of Nanjing Medical UniversityNanjing 210008China department of Hematology/oncology Henan Children's HospitalZhengzhou 450018China department of Pediatric General Surgery Hebei Children's Hospital of Hebei Medical UniversityShijiazhuang City 050031China Children's Hospital the First Affliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of Paediatric

Background This study aimed to identify survival risk factors in Chinese children with hepatoblastoma(HB)and assess the effectiveness of the new treatment protocol proposed by the Chinese Children's Cancer Group(CCCG)in *** A multicenter,prospective study that included 399 patients with HB from January 2015 to June 2020 was *** demographics,treatment protocols,and other related information were *** regression models and Kaplan-Meier curve methods were *** The 4-year event-free survival(EFS)and overall survival(OS)were 76.9 and 93.5%,*** 4-year EFS rates for the very-low-risk,low-risk,intermediate-risk,and high-risk groups were 100%,91.6%,81.7%,and 51.0%,*** 4-year 0S was 100%,97.3%,94.4%,and 86.8%,*** regression analysis found that age,tumor rupture(R+),and extrahepatic tumor extension(E+)were independent prognostic factors.A total of 299 patients had complete remission,and 19 *** with declining alpha-fetoprotein(AFP)>75%after the first two cycles of neoadjuvant chemotherapy had a better EFS and OS than those≤75%.Conclusions The survival outcome of HB children has dramatically improved since the implementation of CCCG-HB-2016 ***≥8 years,R+,and E+were independent risk factors for *** with a declining AFP>75%after the first two cycles of neoadjuvant chemotherapy had better EFS and OS.

关键词： Alpha-fetoprotein Hepatoblastoma Multicenter Prospective study Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Therapeutic effect of Wendan Decoction combined with mosapride on gastroesophageal reflux disease after esophageal cancer surgery

引用

World Journal of Clinical Cases 2024年第13期12卷 2194-2200页

作者： Yu-Jing Zhang Shen-Ping Wu department of oncology Beijing Integrated Traditional Chinese and Western Medicine HospitalBeijing 100039China

BACKGROUND Gastroesophageal reflux disease(GERD)is a common complication of esophageal cancer surgery that can affect quality of life and increase the risk of esophageal stricture and anastomotic *** Decoction(WDD)is a traditional Chinese herbal formula used to treat various gastrointestinal disorders,such as gastritis,functional dyspepsia,and irritable bowel ***,a prokinetic agent,functions as a selective 5-hydroxytryptamine 4 agonist,enhancing gastrointestinal *** To evaluate the therapeutic effects of WDD combined with mosapride on GERD after esophageal cancer *** Eighty patients with GERD were randomly divided into treatment(receiving WDD combined with mosapride)and control(receiving mosapride alone)*** treatment was conducted from January 2021 to January *** primary outcome was improved GERD symptoms as measured using the reflux disease questionnaire(RDQ).The secondary outcomes were improved esophageal motility(measured using esophageal manometry),gastric emptying(measured using gastric scintigraphy),and quality of life[measured via the Short Form-36(SF-36)Health Survey].RESULTS The treatment group showed a notably reduced RDQ score and improved esophageal motility parameters,such as lower esophageal sphincter pressure,peristaltic amplitude,and peristaltic velocity compared to the control *** treatment group showed significantly higher gastric emptying rates and SF-36 scores(in both physical and mental domains)compared to the control *** serious adverse effects were observed in either *** WDD combined with mosapride is an effective and safe therapy for GERD after esophageal cancer *** can improve GERD symptoms,esophageal motility,gastric emptying,and the quality of life of *** studies with larger sample sizes and longer follow-up periods are required to confirm these findings.

关键词： Gastroesophageal reflux disease Esophageal cancer surgery Wendan Decoction Mosapride Treatment effects Gastroesophageal reflux disease symptoms

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

引用

World Journal of Clinical Cases 2024年第2期12卷 285-292页

作者： Sha-Sha Sun Xiao-Di Guo Wen-Dong Li Jing-Long Chen department of oncology Capital Medical University Affiliated Beijing Ditan HospitalBeijing 100015China

BACKGROUND Recently,combination therapy has shown a better trend towards improved tumour response and survival outcomes than monotherapy in patients with hepatocellular carcinoma(HCC).However,research on triple therapy[lenvatinib+sintilimab+transarterial chemoembolization(TACE)]as a first-line treatment for advanced HCC is *** To evaluate the safety and efficacy of triple therapy as a first-line treatment for advanced *** HCC patients with Barcelona Clinic Liver Cancer stage C treated with triple therapy were *** patients were treated with lenvatinib every day and sintilimab once every 3 ***,TACE was performed every 4-6 wk if *** primary outcome of the study was overall survival(OS).The secondary outcomes were the objective response rate(ORR),disease control rate(DCR),and incidence of adverse *** Forty HCC patients who underwent triple therapy were retrospectively analysed from January 2019 to January *** a median follow-up of 8.5 months,the 3-,6-,and 12-mo OS rates were 100%,88.5%,and 22.5%,*** ORR and DCR were 45%and 90%,*** median progressive free survival and median OS were not *** complications were observed in 76%of the patients(grade 3,15%;grade 4,2.5%).CONCLUSiON Combination therapy comprising lenvatinib,sintilimab and TACE achieved promising outcomes in advanced HCC patients and had manageable effects.

关键词： Lenvatinib Sintilimab Advanced hepatocellular carcinoma Combination therapy Tumor response

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optimal orbit transfer of single-tether E-sail with inertially fixed spin axis

引用

Astrodynamics 2024年第2期8卷 285-295页

作者： Alessandro A.Quarta Marco Bassetto Giovanni Mengali department of Civil and industrial Engineering University of PisaPisa I-56122Italy

This study analyzes the optimal transfer trajectory of a spacecraft propelled by a spinstabilized electric solar wind sail(E-sail)with a single conducting tether and a spin axis with a fixed direction in an inertial(heliocentric)reference *** approach proposed in this study is useful for rapidly analyzing the optimal transfer trajectories of the current generation of small spacecraft designed to obtain in-situ evidence of the E-sail propulsion *** this context,starting with the recently proposed thrust model for a single-tether E-sail,this study discusses the optimal control law and performance in a typical two-dimensional interplanetary transfer by considering the(binary)state of the onboard electron emitter as the single control *** resulting spacecraft heliocentric trajectory is a succession of Keplerian arcs alternated with propelled arcs,that is,the phases in which the electron emitter is switched *** particular,numerical simulations demonstrated that a single-tether E-sail with an inertially fixed spin axis can perform a classical mission scenario as a circle-to-circle two-dimensional transfer by suitably varying a single control parameter.

关键词： electric solar wind sail(E-sail) single conducting tether fixed inertial spin axis trajectory optimization circle-to-circle coplanar transfer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Continuously non-malleable codes from block ciphers in split-state model

引用

Cybersecurity 2024年第2期7卷 68-80页

作者： Anit Kumar Ghosal Dipanwita Roychowdhury department of Computer Science and Engineering I KharagpurKharagpurWest BengalIndia

Non-malleable code is an encoding scheme that is useful in situations where traditional error correction or detection is impossible to *** ensures with high probability that decoded message is either completely unrelated or the original one,when tampering has no ***,standard version of non-malleable codes provide security against one time tampering *** ciphers are successfully employed in the construction of non-malleable *** construction fails to provide security when an adversary tampers the codeword more than *** non-malleable codes further allow an attacker to tamper the message for polynomial number of *** this work,we propose continuous version of non-malleable codes from block ciphers in split-state *** construction provides security against polynomial number of tampering attacks and it preserves *** the tam-pering experiment triggers self-destruct,the security of continuously non-malleable code reduces to security of the underlying leakage resilient storage.

关键词： Block cipher Non-malleable code Split-state model Tamper-resilient cryptography

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

引用

oncology Research 2024年第7期32卷 1141-1162页

作者： PAULiNA CHMiEL ALEKSANDRA SŁOWiKOWSKA ŁUKASZ BANASZEK ANNA SZUMERA-CiEĆKiEWiCZ BARTŁOMiEJ SZOSTAKOWSKi MATEUSZ J.SPAŁEK TOMASZŚWiTAJ PiOTR RUTKOWSKi ANNA M.CZARNECKA department of Soft Tissue/Bone Sarcoma and Melanoma Maria Sklodowska-Curie National Research Institute of OncologyWarsaw02-781Poland Faculty of Medicine Medical University of WarsawWarsaw02-091Poland department of Pathology Maria Sklodowska Curie National Research Institute of OncologyWarsaw02-781Poland department of Radiotherapy Maria Sklodowska-Curie National Research Institute of OncologyWarsaw02-781Poland

inﬂammatory myoﬁbroblastic tumor(iMT)is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic *** challenges arise from the diverse pathological presentation,variable symptomatology,and lack of different imaging ***,iMT is identiﬁed by the fusion of the anaplastic lymphoma kinase(ALK)gene,which is present in approximately 70%of cases,with various fusion partners,including ran-binding protein 2(RANBP2),which allows conﬁrmation of the *** surgery is the preferred approach for localized tumors,the optimal long-term treatment for advanced or metastatic disease is difﬁcult to deﬁ*** therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in ***,an ALK tyrosine kinase inhibitor(TKi),was ofﬁcially approved by the US Food and Drug Administration(FDA)in 2020 to treat iMT with ALK ***,most patients face resistance and disease progression,requiring consideration of sequential *** radiotherapy with targeted therapy appears to be beneﬁcial in this *** promising results have also been achieved with immunotherapy,indicating potential for combined therapy ***,deﬁned recommendations are still *** review analyzes the available research on iMT,including genetic disorders and their impact on the course of the disease,data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication,as well as summarizing general knowledge about prognostic and predictive factors,also in terms of resistance to systemic therapy.

关键词： inﬂammatory myoﬁbroblastic tumor(iMT) Epithelioid inﬂammatory myoﬁbroblastic sarcoma Tyrosine kinase inhibitors(TKi) Anaplastic lymphoma kinase(ALK)

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

To drain or not to drain after distal pancreatectomy: reflexions on the PANDORiNA trial

引用

Hepatobiliary Surgery and Nutrition 2024年第4期13卷 675-677页

作者： Maxime Constant Alexandre Doussot department of Digestive and Surgical oncology Liver Transplantation UnitCHU BesanconBesançonFrance

We read with great interest the PANDORiNA study(1).This international multicenter(mostly from the Netherlands)randomized controlled trial aimed at determining whether omitting drainage after distal pancreatectomy(DP)was equivalent in terms of complications to systematic drainage *** primary outcome was the occurrence of severe complications at 90 days defined as Dindo-Clavien grade≥*** main secondary outcome was the occurrence of grade B–C postoperative pancreatic fistula(POPF)at 90 *** both outcomes,the non-inferiority threshold was set at 8%.Randomization was performed intraoperatively,stratified by annual center volume(high volume defined as DP≥40/year)and the risk of POPF according to the distal fistula risk score(D-FRS)combining pancreas thickness(high risk,>19 mm)and main pancreatic duct diameter(high risk,>3 mm)measured both at the isthmus(2).

关键词： Drainage distal pancreatectomy(DP) randomized controlled trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation:A multicenter,case-series study in China

引用

Chinese Journal of Cancer Research 2024年第4期36卷 398-409页

作者： Shouzheng Wang Jiayu Liu Yan Wang Ying Hu Ziling Liu Yu Yao Li Liang Yutao Liu Lin Wang Junling Li Puyuan Xing department of Medical oncology National Cancer Center/National Clinical Research Center for Cancer/CancerHospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China department of Medical oncology Beijing Chest HospitalCapital Medical UniversityBeijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China Cancer Center the First Hospital of Jilin UniversityChangchun 130021China department of Medical oncology the First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China department of Medical oncology and Radiation Sickness Peking University Third HospitalBeijing 100191China

Objective:To provide real-world evidence for the application of first-line dacomitinib treatment for epidermal growth factor receptor(EGFR)21L858R mutant non-small cell lung cancer(NSCLC)patients in China and to explore the factors influencing the efficacy and ***:A longitudinal,consecutive case-series,multicenter study with mixed prospective and retrospective data was *** primary endpoint was progression-free survival(PFS),and the secondary endpoints included duration of treatment(DOT),overall survival(OS),objective response rate(ORR),disease control rate(DCR)and ***:A total of 155 EGFR 21L858R mutant patients treated with first-line dacomitinib were *** median follow-up time for these patients was 20.4 *** 134 patients with evaluable lesions,the ORR was 70.9%and the DCR was 96.3%.The median PFS was 16.3[95%confidence interval(95%Ci),13.7−18.9]*** Cox regression analysis suggested that the baseline brain metastasis(BM)status[with *** BM:hazard ratio(HR),1.331;95%Ci,0.720−2.458;P=0.361]and initial doses(45 mg vs.30 mg:HR,0.837;95%Ci,0.427−1.641;P=0.604)did not significantly affect the median *** median DOT was 21.0(95%Ci,17.5−24.6)months and the median OS was not *** tests were performed in 64 patients after progression,among whom 29(45.3%)patients developed the EGFR 20T790M *** addition,among the 46 patients who discontinued dacomitinib treatment after progression,31(67.4%)patients received subsequent third-generation EGFR-tyrosine kinase *** most common grade 3−4 adverse events were rash(10.4%),diarrhea(9.1%),stomatitis(7.1%)and paronychia(4.5%).The incidence of grade 3−4 rash was significantly higher in the 45 mg group than that in the 30 mg group(21.9%vs.7.5%,P=0.042).Conclusions:First-line dacomitinib treatment demonstrated promising efficacy and tolerable adverse events among EGFR 21L858R mutant NSCLC patients in China.

关键词： Epidermal growth factor receptor molecular targeted therapy non-small cell lung cancer safety treatment efficacy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

insights on liver-directed surgical innovations, targeted therapies, and immunotherapy for biliary tract cancer: navigating the new European Society for Medical oncology (ESMO) Clinical Practice Guidelines

引用

Hepatobiliary Surgery and Nutrition 2024年第3期13卷 516-519页

作者： Ajay V.Maker Division of Surgical oncology Department of SurgeryUniversity of CaliforniaSan FranciscoCAUSA

Cancers of the bile duct,including gallbladder cancer,extrahepatic cholangiocarcinoma,hilar and intrahepatic cholangiocarcinoma,present a significant treatment *** by their notorious difficulty to diagnose or biopsy,intricate anatomical locations and diverse clinical presentations,these malignancies collectively contribute to a significant burden on global *** epidemiology of bile duct cancers reveals worldwide variations in incidence,prevalence,and mortality rates,emphasizing the need for a nuanced understanding of each subtype and the local environmental *** in early diagnosis further compound the complexity of managing these cancers,often leading to advanced stage at the time of detection and treatment *** remains the cornerstone of curative-intent treatment of bile duct cancers,yet the rate of recurrence and metastases underscores the importance of comprehensive multidisciplinary therapeutic *** randomized clinical trials have been performed;however,they have been challenged by the lack of active agents,a limited number of accrued patients,and a grouping of all patients together regardless of where in the biliary tract the tumor *** has resulted in variations in treatment strategies and multiple treatment options that range from immunotherapy to radiation to hepatic artery infusion therapy(more on this later).A greater understanding of the mutational landscape of biliary tract cancers has resulted in optimism around appropriately targeted agents and combination ***,many of these regimens await robust outcomes data,and it is questionable if they significantly move the needle forward to improve overall *** now,more than ever,there is a need for updated treatment guidelines.

关键词： Gallbladder cancer cholangiocarcinoma guidelines bile duct cancer hepatic artery infusion pump

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Multifaceted role of microRNAs in gastric cancer stem cells: Mechanisms and potential biomarkers

引用

World Journal of Gastrointestinal oncology 2024年第2期16卷 300-313页

作者： Qian-Hui Sun Zi-Yu Kuang Guang-Hui Zhu Bao-Yi Ni Jie Li department of oncology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijing 100053China Graduate College Beijing University of Traditional Chinese MedicineBeijing 100029China department of oncology Heilongjiang University of Chinese MedicineHarbin 150040Heilongjiang ProvinceChina

MicroRNAs(miRNAs)have received much attention in the past decade as potential key epigenomic regulators of tumors and cancer stem cells(CSCs).The abnormal expression of miRNAs is responsible for different phenotypes of gastric cancer stem cells(GCSCs).Some specific miRNAs could be used as promising biomarkers and therapeutic targets for the identification of *** review summarizes the coding process and biological functions of miRNAs and demon-strates their role and efficacy in gastric cancer(GC)metastasis,drug resistance,and apoptosis,especially in the regulatory mechanism of *** shows that the overexpression of onco-miRNAs and silencing of tumor-suppressor miRNAs can play a role in promoting or inhibiting tumor metastasis,apart from the initial formation of *** also discusses the epigenetic regulation and potential clinical applications of miRNAs as well as the role of CSCs in the pathogenesis of *** believe that this review may help in designing novel therapeutic approaches for GC.

关键词： Gastric cancer,Cancer stem cells MicroRNAs Epigenetics Therapeutic target

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：